author-photo

Jonathan Janes

Eli Lilly and Company

55

Papers

3206

Citations

Citation Trend

Filter By

Papers (33) Sort By

Journal Conference Others

Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study

2021 Journal of The American Academy of Dermatology
Show All
- Source
- Cite
- Save
Citations (3)
041 Efficacy with continuous dosing, down-titration, or treatment withdrawal after successful treatment with baricitinib in patients with moderate-to-severe atopic dermatitis

2021 Journal of Investigative Dermatology
Show All
- Source
- Cite
- Save
Citations (0)
Insights into adult atopic dermatitis heterogeneity derived from circulating biomarker profiling in patients with moderate-to-severe disease.

2021 Experimental Dermatology
Show All
- Source
- Cite
- Save
Citations (3)
26585 Baricitinib for the treatment of pediatric patients with moderate-to-severe atopic dermatitis

2021 Journal of The American Academy of Dermatology
Show All
- Source
- Cite
- Save
Citations (0)
Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy Phase 3 trial in the United States and Canada (BREEZE-AD5).

2021 Journal of The American Academy of Dermatology
Show All
- Source
- Cite
- Save
Citations (11)
Efficacité et sécurité du baricitinib associé à des corticostéroïdes topiques (TCS) dans le traitement de la dermatite atopique (DA) modérée à sévère : étude de phase 3 de 16 semaines en double aveugle, randomisée et contrôlée vs placebo (BREEZE-AD7)

2020 Annales De Dermatologie Et De Venereologie
Show All
- Source
- Cite
- Save
Citations (0)
199 Baricitinib in patients with systemic lupus erythematosus: results from a phase 2, randomized, double-blind, placebo-controlled study

2019 Lupus science & medicine
Show All
- Source
- Cite
- Save
Citations (2)
JAK1/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a Phase 2 randomized controlled clinical trial

2018 Nephrology Dialysis Transplantation
Show All
- Source
- Cite
- Save
Citations (102)
Pharmacokinetics, Pharmacodynamics, and Proposed Dosing of the Oral JAK1 and JAK2 Inhibitor Baricitinib in Pediatric and Young Adult CANDLE and SAVI Patients

2018 Clinical Pharmacology & Therapeutics
Show All
- Source
- Cite
- Save
Citations (53)
JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies

2018 Journal of Clinical Investigation
Show All
- Source
- Cite
- Save
Citations (229)